Human Papilloma Virus Clinical Trial
Official title:
A Practice-Provider-Parent-Adolescent Intervention to Increase HPV Vaccination
The primary research aim of this project is to test the effectiveness of a comprehensive,
evidence-based vaccine promotion toolkit implemented in the pediatric healthcare setting on
increasing the likelihood that adolescents in Georgia will initiate and complete the Human
Papillomavirus (HPV) vaccine series. Secondary research aims include assessing the impact of
the comprehensive toolkit on 1) patient and parent knowledge and attitudes regarding HPV
vaccine, and 2) provider recommendation of HPV vaccine for males and females in the
recommended age range (11-12 years). The intervention toolkit will include evidence-based
components aimed at the practice-level, provider-level and parent-level that will be tested
through a cluster-randomized trial design. The primary hypothesis is that implementation of
the comprehensive vaccine promotion toolkit in the pediatric health care setting will
increase the likelihood that an adolescent receives initiates HPV vaccination.
At the initial visit, parents of adolescent patients at participating pediatric practices
will complete a brief questionnaire assessing their knowledge, attitudes, and beliefs about
adolescent health, including protection against infectious diseases during adolescence. The
parents will be contacted again three months later to complete a short follow-up interview on
the general health of their adolescent child, immunization status, and attitudes regarding
vaccination.
Since the introduction of HPV vaccine, there have been a number of studies examining
attitudes and barriers related to HPV vaccine uptake among adolescent and young adult women,
parents, and healthcare providers. Through these surveys, a number of distinct themes
regarding reasons for not taking the HPV vaccine have emerged, including lack of provider
recommendation, lack of awareness about the vaccine and the need for vaccination, concerns
about vaccine effectiveness, concerns about vaccine safety, the potential of a vaccine
against a sexually transmitted infection to increase promiscuity, cost of the vaccine doses,
and the lack of routine adolescent well-care visits. However, many of these studies have used
endpoints related to HPV vaccine knowledge or intention to vaccinate rather than actual
vaccination uptake. Interventions that use endpoints related to vaccination uptake rather
than knowledge or intention to vaccinate, as well as those that address multiple levels of
the healthcare decision making process, will be crucial in addressing routine immunization
coverage among adolescents. At the end of the evaluation of this intervention package, the
researchers of this study hope to have identified a comprehensive and easily scalable
"shelf-ready" toolkit aimed at increasing uptake of vaccines that are indicated during
adolescence. If successful, this package could easily be implemented on a national level.
In the evaluation study, the researchers will use a cluster-randomized trial design to test
whether exposure to the intervention package increases the likelihood of vaccine receipt by
an adolescent in a practice randomized to receive the intervention package compared to an
adolescent in a practice randomized to the control (standard of care) arm. Participating
pediatric practices will be pair-matched based on overall adolescent patient load and
historical HPV vaccine uptake and pairs will be randomized to one of two study arms:
1. Intervention arm: The pediatric practices randomized to this arm will receive the
comprehensive adolescent vaccine promotion package. Practice physicians and staff will
be familiarized with each component, and practices will be instructed to implement each
vaccine-promotion component to the best of their ability.
2. Control arm: The pediatric practices randomized to the control arm will not receive the
comprehensive vaccine promotion package and will instead be instructed to continue
offering their standard adolescent vaccination promotion practices to adolescent
patients.
Parents of eligible adolescents at participating practices will be given the opportunity to
take part in this study. At the initial visit, parents of adolescent patients will complete a
brief questionnaire assessing their knowledge, attitudes, and beliefs about adolescent
health, including protection against infectious diseases during adolescence. The parents will
be contacted again three months later to complete a short follow-up interview on the general
health of their adolescent child, immunization status, and attitudes regarding vaccination.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05329961 -
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
|
Early Phase 1 | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Active, not recruiting |
NCT04199078 -
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
|
N/A | |
Recruiting |
NCT05566106 -
Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
|
||
Not yet recruiting |
NCT06436274 -
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
|
Phase 4 | |
Not yet recruiting |
NCT06229353 -
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
|
||
Completed |
NCT01757392 -
Candin Safety & Efficacy Study for the Treatment of Warts
|
Phase 2 | |
Active, not recruiting |
NCT04716127 -
A Proximity-incentive Strategy for Cervical Cancer Screening
|
N/A | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Recruiting |
NCT05835947 -
Anal Cancer Risk In Women
|
||
Not yet recruiting |
NCT03947775 -
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
|
Phase 2 | |
Terminated |
NCT03404310 -
Zinc Sulfate for Human Papillomavirus (HPV)
|
N/A | |
Recruiting |
NCT03302858 -
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand
|
Phase 2 | |
Completed |
NCT03082950 -
HPV Infections, Cancer of the Vulva and Therapeutical Success
|
||
Active, not recruiting |
NCT04950101 -
Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis
|
N/A | |
Recruiting |
NCT05146895 -
A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts
|
N/A | |
Completed |
NCT04002154 -
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
|
N/A | |
Recruiting |
NCT04232917 -
Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.
|
Phase 4 | |
Active, not recruiting |
NCT03729518 -
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
|
N/A | |
Recruiting |
NCT05640700 -
Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
|